Project Grant R43CA277895

Award Date 4/1/23
Completion Date 3/31/24
Dollars Obligated $400K
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Washington, DC, USA
Similar Awards
This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), provides $309,974 to support the development of a novel, low-cost device called LIVERscope. The LIVERscope device uses advanced magnetic resonance (MR) technology to noninvasively estimate quantitative biomarkers of nonalcoholic fatty liver disease (NAFLD), including liver...
The National Science Foundation (NSF) awarded a $459,039 CAREER grant under the Engineering program (CFDA 47.041) to the University of Alabama at Birmingham (UAB) for a project titled "HEAT PENETRATION DEPTH AND DIRECTION CONTROL WITH CLOSED-LOOP DEVICE FOR PRECISION ABLATION". This 5-year project aims to develop a novel ablation catheter that can precisely control heat penetration and direction during thermal ablation procedures, with the goal of improving the efficacy and safety of...
This U01 Cooperative Agreement award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $357,939 to the University of California, Davis to develop a "Liver Digital Twin for Personalized Cancer Therapy." The project aims to improve the efficacy and safety of liver cancer transarterial embolization (TAE) procedures by creating computational models and optimization algorithms to enable personalized treatment...
This $2,291,527 Project Grant awarded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" (CFDA 93.286) program supports the development and validation of an ultrafast, bubble-specific ultrasound imaging system to monitor histotripsy, a noninvasive focused ultrasound therapy, for the treatment of renal cell carcinoma (RCC). The key objectives are to: 1) Integrate...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Cooperative Agreement award of $1,000,000 to Theromics Inc., a minority-owned small disadvantaged business, aims to develop a novel protein-based gel to improve the effectiveness and safety of thermal tumor ablation procedures. The project will involve creating a computational model to predict the thermal behavior of the gel, conducting preclinical studies to quantify temperatures, ablation zone size,...
This federal Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), is funding the development of a novel laser-guided drug delivery system to prevent tumor recurrences after surgical resection. The $374,095 award to Oncoblaze LLC, based in Charleston, SC, supports the development of thermo-sensitive liposomal nanoparticles that can...
This STTR Phase I project, funded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), aims to advance the development and evaluation of a hand-held induction heater device for treating pancreatic and prostate cancer using magnetic fluid hyperthermia (MFH) technology. The project, awarded to Ihnnova LLC, a small business located in Guánica, Puerto Rico, will receive $275,000 in funding over the period of October 1, 2024 to...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $275,092 to the University of Wisconsin - Madison to develop an accurate and robust technique for transcostal (through the ribs) targeting of liver tumors using histotripsy, an emerging non-invasive, non-thermal cancer treatment. The key objectives are to: 1) Quantify the effects of intervening ribs on targeting accuracy through ex-vivo and in-vivo experiments; 2) Develop a machine...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $536,836 to The University of Texas MD Anderson Cancer Center to develop mathematical models and computational methodologies to optimize the delivery of a transarterial ablative therapy for treating hepatocellular carcinoma. The key objectives are to: Formulate mathematical models that capture the complex multiphase flow, heat transfer, and chemical reactions occurring...
This $275,000 Small Business Technology Transfer (STTR) Phase I grant from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships program) was awarded to Oncoblaze LLC to develop a novel device for targeted delivery of chemotherapy agents to tissue surrounding surgically removed tumors. The project aims to address the issue of tumor recurrence after cancer surgery, which affects 30-40% of patients for certain cancers. The device uses an infrared laser to heat...

IN VIVO FEASIBILITY OF A SMART NEEDLE ABLATION TREATMENT FOR LIVER CANCER - PROJECT SUMMARY A SIGNIFICANT NUMBER (~30-50%) OF LIVER CANCERS HAVE NO CURATIVE TREATMENTS DUE TO THEIR PROXIMITY TO CRITICAL ANATOMY. MINIMALLY INVASIVE THERMAL ABLATION IS A PROMISING TREATMENT FOR THESE UNTREATABLE SOLID TUMORS. IF DELIVERED PRECISELY, ABLATIONS OFFER THE TREATMENT EFFICACY OF TRADITIONAL SURGERY WITH LOWER PATIENT RISK, CLINICIAN TIME, AND OVERALL COST. EXISTING ABLATION TECHNOLOGY, HOWEVER, DOES NOT OFFER THE NECESSARY PRECISION. ABLATION TOOLS DO NOT PROVIDE FEEDBACK ON (1) WHETHER OR NOT THE PROBE HAS BEEN ACCURATELY PLACED WITHIN THE TUMOR, (2) IF THE TUMOR HAS BEEN COMPLETELY DESTROYED, OR (3) IF SURROUNDING HEALTHY TISSUE HAS BEEN LEFT INTACT. BECAUSE OF THIS LACK OF PRECISION AND FEEDBACK, ABLATION CANNOT CURRENTLY BE USED TO TREAT TUMORS NEAR CRITICAL ANATOMY. A PROPOSED SOLUTION TO THESE CURRENTLY UNTREATABLE CANCERS IS AN ULTRAPRECISE ABLATION NEEDLE, EMBEDDED WITH HIGH-RESOLUTION ULTRASOUND SENSORS AT ITS TIP. THESE SENSORS WILL PROVIDE MULTIPLE BENEFITS: AIDING THE CLINICIAN IN PLACING THE DEVICE CORRECTLY BY IMAGING THE TUMOR RELATIVE TO THE NEEDLE, DELIVERING THE TREATMENT ENERGY TO A PRECISE LOCATION THROUGH FOCUSING, AND PROVIDING REAL-TIME MONITORING OF THE PROCEDURE BY DETECTING THE THERMAL CHANGES IN TISSUE-ALL WITHOUT THE NEED FOR A LARGE IMAGING SYSTEM. THIS INNOVATION WILL ALLOW SURGEONS TO COMPLETE AN ABLATION WITH THE REQUIRED PRECISION TO TREAT EVEN THE MOST DIFFICULT-TO-REACH CANCERS. THIS PHASE 1 SBIR PROPOSAL WILL DEMONSTRATE THE CAPABILITIES OF SMALL-SCALE ULTRASOUND TRANSDUCERS TO PRECISELY CONTROL ABLATIONS NEAR CRITICAL ANATOMICAL STRUCTURES (E.G., ARTERIES) IN AN IN VIVO PORCINE MODEL THROUGH THREE SPECIFIC AIMS: (1) OPTIMIZATION OF PREVIOUSLY DEVELOPED ULTRASOUND-BASED ABLATION ZONE ESTIMATION IN EX VIVO LIVER TISSUE USING DEEP LEARNING AND PHYSICS-BASED SIMULATIONS, (2) ABLATION ZONE ESTIMATION IN AN IN VIVO PORCINE LIVER MODEL, AND (3) DEMONSTRATION OF IN VIVO CLOSED-LOOP ABLATION ZONE CONTROL NEAR CRITICAL ANATOMY (ARTERY IN LIVER). COMPLETION OF THIS PHASE WILL DEMONSTRATE THE KEY TECHNOLOGY IN A PILOT ANIMAL STUDY, WHERE PHASE 2 WORK WOULD ADDRESS CRITICAL DEVELOPMENT MILESTONES TO COMMERCIALIZATION FOR AN ANTICIPATED CLASS 2 DEVICE (APPROVAL VIA DE NOVA REGULATORY PATHWAY).

Posted 3/28/23, 12:00 AM